Circle Pharma and Verismo feature in coveted sessions.
ApexOnco Front Page
Recent articles
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
It’s less about being fast, more about producing a better product.
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The company will try to get the Komzifti QTc prolongation warning removed.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
